Zenas Biopharma, INC Schedule 13D activist filings

SR One Capital Management and affiliated entities have amended their Schedule 13D filing to reflect a decrease in their beneficial ownership percentage of Zenas BioPharma, Inc. common stock.

Leon O. Moulder, Jr., CEO of Zenas BioPharma, along with affiliated entities, has disclosed beneficial ownership of 5.09% of the company's common stock.

Leon O. Moulder, Jr. and associated entities report a combined 4.79% stake in Zenas BioPharma following recent share acquisitions.

Zenas BioPharma's CEO and Chairman, Leon O. Moulder, Jr., along with affiliated entities, reported an aggregate beneficial ownership of 5.159% of the company's common stock, following recent open-market purchases and a private placement.

Enavate Sciences and Zebra Aggregator increased their beneficial ownership in Zenas BioPharma to 7.3% following participation in a $120 million private placement.

SR One Capital Management and affiliated funds increased their beneficial ownership in Zenas BioPharma, Inc. to 9.4% through a recent private placement.

Longitude Capital and its affiliates, along with director Patrick Enright, reported a decrease in their beneficial ownership of Zenas BioPharma to below 5% following a recent private placement.

Zenas BioPharma's CEO, Leon O. Moulder, Jr., and affiliated entities increased their beneficial ownership to 4.8% following a private placement that closed on October 9, 2025.

Zenas BioPharma, Inc.'s CEO and Chairman, Leon O. Moulder, Jr., along with Tellus BioVentures, LLC, have filed a Schedule 13D disclosing a combined beneficial ownership of 5.0% of the company's common stock, held for general investment purposes.